Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The Freeze-dried Human Rabies Vaccine is an inactivated vaccine developed and manufactured by Ningbo Rongan Biological Pharmaceutical, a subsidiary of AIM Vaccines. It is produced using either Vero cell or human diploid cell technology to propagate the rabies virus, which is then inactivated and lyophilized for stability. The vaccine is indicated for both pre-exposure and post-exposure prophylaxis against rabies, a lethal zoonotic disease. It works by stimulating the immune system to produce virus-neutralizing antibodies that provide protective immunity. The vaccine is approved in China and has been evaluated in Phase III clinical trials using various immunization schedules, including the 5-dose, 4-dose, and 2-1-1 regimens, demonstrating high immunogenicity and a favorable safety profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rabies vaccine (Ningbo Rongan Biological Pharmaceutical Co., Ltd.).